Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bellmunt

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinomaB A McGregor, G P Sonpavde, L Kwak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetateP Dombernowsky, I Smith, G Falkson, et al.
Clinical Genitourinary Cancer|June 6, 2016
Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial CarcinomaG Sonpavde, G R Pond, G Di Lorenzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapyK Fizazi, A Ulys, L Sengeløv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 23, 2020
Latest progress in molecular biology and treatment in genitourinary tumoursA González-Del-Alba, J Á Arranz, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinomaT K Choueiri, A P Fay, K P Gray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinomaJ Garcia-Donas, L J Leandro-García, A González Del Alba, et al.
Clinical Genitourinary Cancer|July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial designG R Pond, J Bellmunt, J E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trialT Powles, S Tagawa, C Vulsteke, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinomaB A McGregor, G P Sonpavde, L Kwak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetateP Dombernowsky, I Smith, G Falkson, et al.
Clinical Genitourinary Cancer|June 6, 2016
Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial CarcinomaG Sonpavde, G R Pond, G Di Lorenzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapyK Fizazi, A Ulys, L Sengeløv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 23, 2020
Latest progress in molecular biology and treatment in genitourinary tumoursA González-Del-Alba, J Á Arranz, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinomaT K Choueiri, A P Fay, K P Gray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinomaJ Garcia-Donas, L J Leandro-García, A González Del Alba, et al.
Clinical Genitourinary Cancer|July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial designG R Pond, J Bellmunt, J E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trialT Powles, S Tagawa, C Vulsteke, et al.
Pageof 13